Microsoft word - cistiprost ingl.doc

CISTIPROST
"The herbal remedy to help maintain the physiological function of the prostate and bladder " Brief information The Cistiprost is a nutraceutical made with plant extracts titrated and selected according to them specific and overt activities and associated to provide with a synergy of action, a valid protection for prostate function and for irritations and inflammation of the bladder, which are often attributable to a pathological condition of the prostate. The Cistiprost represents a real novelty for the completeness of its formulation, synergism, purity, stability of its components, some of which are covered by worldwide patent for the extraction method. All components in Cistiprost have been and continue to be studied and used by leading international research institutes (see bibliography). Observations on the pathology of prostatic hypertrophy The infectious and metabolic problems born by the prostate gland are a frequent cause of urological consultation. Often the prostate gland disorders, classified as benign prostatic hyperplasia (BPH) and prostate cancer, are often connected with aging as well as causes of infectious and mechanical. Alterations in the prostate microenvironment, due to events associated with aging and senescence stromal and / or bacterial events, obstructive, mechanical (eg, cycling and horse riding) are causes that contribute to the injury of contributing to diseases of this organ. The muscle fibers and fibroblasts of the prostate may manifest more in old age, alterations at the molecular level due to inflammatory stimuli, the basic factor of prostate disease. During the course of inflammatory diseases has been noted, in fact, that IL-8 stimulates the growth of the apparatus prostate and increases the detection of T-lymphocytes, macrophages and cytokines: alterations that occur even during the Benign Prostatic Hyperplasia. In this regard, the components of the Cistiprost intervene specifically to the various agents involved in the development of inflammatory disease, prostatic hypertrophy. The risk of BPH is increased by the concomitant presence of metabolic syndrome: the increase in prostate volume is mainly linked to hypertension, obesity and diabetes. This can be explained considering that hyperinsulinemia is connected with an increase in sympathetic activity that leads to an activation of the α - receptor, present on the prostate tissue and on the neck of the bladder, and thus contributes to the symptoms. Furthermore hypertension appears to be an important factor that increases the incidence of hematuria in patients with BPH. In most cases, whatever the exact nature of the complaint or the predominant component (infectious, inflammatory, obstructive pulmonary disease, etc.), the patient has a set of symptoms broadly comparable with signs prevalent in lower urinary and sexual. tract. In recent years this symptom, present in varying degrees in all benign prostate disease, has been described as LUTS (Lower Urinary Tract Symptoms) and is characterized by disturbances such as urinary visuria, urgency, nocturia, dysuria, poor stream, incomplete emptying. These diseases also lead to sexual disorders (painful ejaculation, azoospermia, etc.), but the main symptom of all is the pelvic pain. The presence of chronic inflammation may be the bridge between chronic prostatitis and benign prostatic hyperplasia with fibromuscular proliferation typical of BPH. Based on numerous histopathological, pharmacological and morphofunctional findings we can assume the existence of a pathogenic condition (inflammatory syndrome) common in prostatitis, benign prostatic hypertrophy and possibly prostate cancer. It is clear that to intervene and improve a prostate disorder is necessary to combine an activity anti: inflammatory, bacterial, tumor with a muscle relaxant component and anti-oxidant. To this end, Cistiprost through the many activities, scientifically attributed to its components (see below), involved in countering and combating the various factors responsible for prostate and bladder disease, also contributing to a significant improvement in quality of life of patients . It 's especially important to highlighted that the individual components present in CISTIPROST, have not caused, even during significantly prolonged recruitment, changes in the hormone system, which instead are well known to other products anti-prostate. CISTIPROST can also be taken together and in support to a drug therapy. BIBLIOGRAPHY Matthias Oelke, Martin C. Michel What do we really know about benign prostatic hyperplasia and lower urinary tract symptoms in adult men? Hannover Medical School, Germany e University of Amsterdam, World J Urol (2011) 29:141–142 DOI 10.1007/s00345-011-0664-5 Yallapu MM, Jaggi M, Chauhan SC. beta-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. USA. Colloids Surf B Biointerfaces. 2010 Aug 1;79(1):113-25. Epub 2010 Apr 3. Marie-He´le`ne Teiten, Franc¸ois Gaascht, Serge Eifes, Mario Dicato, Marc Diederich Chemopreventive potential of curcumin in prostate cancer Luxembourg, Luxembourg Genes Nutr (2010) 5:61–74 DOI 10.1007/s12263-009-0152-3 N Krzysztof Waliszewski, DSC, Blasco Gabriela, MSc Proprietà nutraceutiche del licopene, Messico Salud Publica Mex vol. 52 n.3 Cuernavaca maggio/giugno 2010 Moon DO, Kang CH, Kim MO, Jeon YJ, Lee JD, Choi YH, Kim GY. Beta-lapachone (LAPA) decreases cell viability and telomerase activity in leukemia cells: suppression of telomerase activity by LAPA. Republic of Korea. J Med Food. 2010 Jun;13(3):481-8. Daniella Bianchi-Frias, Funda Vakar-Lopez, Ilsa M. Coleman, Stephen R. Plymate, May J. Reed, Peter S. Nelson The Effects of Aging on the Molecular and Cellular Composition of the Prostate Microenvironment Washington, September 1, 2010 GUO Li-jun, TANG Yuan, GUO Chao-ming and ZHANG Xiang-hua Impact of primary hypertension on hematuria of the patients with benign prostatic hyperplasia Peking University, Gansu Province People Hospital, Lanzhou, Chin Med J 2010;123(9):1154-1157 Camila B. Piantino, Fernanda A. Salvadori, Pedro P. Ayres, Raphael B. Kato, Victor Srougi, Katia R. Leite, Miguel Srougi An Evaluation of the Anti-neoplastic Activity of Curcumin in Prostate Cancer Cell Lines Laboratory of Medical Investigation (CBP, FAS, PPA, RBK, VS, KRL, MS), Sao Paulo, Brazil International Braz J Urol Vol. 35 (3): 354-361, May - June, 2009 Lívia L. Corrêa1, Giovanna A. Balarini Lima, Helena B. de Melo Paiva, Cíntia M. dos Santos Silva, Suzana A. Cavallieri, Luiz Carlos D. de Miranda, Mônica R. Gadelha Prostate cancer and acromegaly Brasil Arq Bras Endocrinol Metab. 2009;53(8):963-8 Marion E. T. McMurdo1, Ishbel Argo, Gabby Phillips, Fergus Daly and Peter Davey Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women School, University of Dundee, Scotland, UK Journal of Antimicrobial Chemotherapy (2009) 63, 389–395 Wertz K. Lycopene effects contributing to prostate health DSM Nutritional Products Ltd., Basel, Switzerland Nutr Cancer 2009 Nov; 61(6):775-83 Chan R, Lok K, Woo J. Prostate cancer and vegetable consumption. Mol Nutr Food Res. 2009 Feb;53(2):201-16. Andrzejewski T, Deeb D, Gao X, Danyluk A, Arbab AS, Dulchavsky SA, Gautam SC. Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Department of Surgery, Detroit, MI, USA. Oncol Res. 2008;17(6):257-67. Eyong KO, Kumar PS, Kuete V, Folefoc GN, Nkengfack EA, Baskaran S. Semisynthesis and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone derivatives from lapachol. Indian Institute of Technology Madras, India. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5387-90. Epub 2008 Sep 17. Lien YC, Kung HN, Lu KS, Jeng CJ, Chau YP. Involvement of endoplasmic reticulum stress and activation of MAP kinases in beta-lapachone-induced human prostate cancer cell apoptosis. Taiwan. Histol Histopathol. 2008 Nov;23(11):1299-308. Thore Santel, Gabi Pflug, Nasr Y. A. Hemdan, et all. Curcumin Inhibits Glyoxalase 1—A Possible Link to Its Anti-Inflammatory and Anti-Tumor Activity Institute of Biochemistry, Germany Daniel Tome October 23, 2008 Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cancer Care Research Centre Stirling, UK Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001321. Ke-Hung Tsui et al. Curcumin Blocks the Activation of Androgen and Interlukin-6 on Prostate-Specific Antigen Expression in Human Prostatic Carcinoma Cells Department of Urology and the Molecular Image Center Taiwan, Republic of China. Jepson RG, Craig JC. A systematic review of the evidence for cranberries and blueberries in UTI prevention. University of Stirling, UK Mol Nutr Food Res. 2007 Jun;51(6):738-45. Catherine C. Neto Cranberry and Its Phytochemicals: A Reviewof In Vitro Anticancer Studies University of Massachusetts–Dartmouth J. Nutr. 137: 186S–193S, 2007. Salman H, Bergman M, Djaldetti M, Bessler H. Lycopene affects proliferation and apoptosis of four malignant cell lines. Tel-Aviv University, Ramat-Aviv, Israel.Biomed Pharmacother. 2007 Jul;61(6):366-9. Epub 2007 Mar 19. Sharmila Shankar and Rakesh K. Srivastava Involvement of Bcl-2 family members, phosphatidylinositol 3-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer, University of texas Health Center, Tyler International Journal of Oncology 30: 905-918, 2007 Kim SO, Kwon JI, Jeong YK, Kim ND, Choi YH, Lapacho tree (Tabebuia avallanedae) anti-infiammatory and anti-cancer activities. Dongeui University College of Oriental Medicine. Biosci Biochem. 2007 Sep; 71(9): 2196-76 2007 Sep. 7 Liu Y, Black MA, Caron L, Camesano TA. Role of cranberry juice on molecular-scale surface characteristics and adhesion behavior of Escherichia coli. Worcester Polytechnic Institute Biotechnol Bioeng. 2006 Feb 5;93(2):297-305. Edward H. Oswald Rapporto descritivo, analitico e delle attività del “Lapacho- Tabebuia” da british Journal of Phytotherapy, vol. 3 n. 3, 1993/1994 Ammon HP, Safayhi H, Mack T, Sabieraj J. Mechanism of antiinflammatory actions of curcumine and boswellic acids. Department of Pharmacology, Tübingen, FRG. J Ethnopharmacol. 1993 Mar;38(2-3):113-9. Oga S. and Sekino T: Toxicidade e atividade anti-inflamatoria de Tabebuia Avell. Lorentz e Griesbach. Rev Fac Farm Bioquim S. Paulo 7, 47-53, 1969 How to use: 1-2 tablets per day, according to medical opinion, preferably at least one hour before meals. Contraindications: do not be carried over the recommended dosage of each ingredient. Possible rare episodes of individual hypersensitivity. Note for guidance: if the patients undergoing drug therapy is forced to stop the treatment procedure, due to possible side effects of medication, individual intolerance or temporary discontinuation of drug therapy, the Cistiprost can be useful in continuing the control of homeostasis of referee organs. Read and follow the specific assessment of your doctor,before you start taking the N.B. All information regarding the activities of the various ingredients in Cistiprost, are reflected in publications of University Institutes, international researchers and Various Authors, available on the website of free access (www.pubmed.gov inserting into the search engine the names of the individual components). This summary has as its goal to brink back some of the possible benefits that the components present in Cistispost can contribute to make. PHARMACEUTICAL & BIO-NATURAL COMPANY
Registered at the Health Minister Registrar No. 1599 Registration at the Turin Court No. 2431/92 – Chamber of Commerce of Turin No. 0778545 – VAT Registration No. 06328630014 Headquarters: Via Garzigliana 8 – 10127 Turin Italy Administr. Offices and Stocking Area: Via Beinette 8/D – 10127 Turin Italy – Phone + 39 011 6961244 – Fax + 39 011 6787072 e-mail address: europharma@libero.it Website : www.europharma.it

Source: http://www.europharma.it/sito/images/integratori/cistiprost-en.pdf